Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Novo Nordisk is looking into whether smaller doses of its Wegovy pill can still help people lose weight. A new clinical trial kicked off on August 12, and it’s already drawing attention across the pharmaceutical world.
The study will follow 450 adults. Researchers want to find out if lower doses of semaglutide, the active ingredient in Wegovy, can deliver real results with fewer side effects. That’s a meaningful question, since nausea and stomach issues send many patients off these medications early.
Right now, Wegovy pills come in four strengths: 1.5 milligrams, 4 milligrams, 9 milligrams, and 25 milligrams. Doctors typically consider 25 milligrams the maintenance dose. But this trial goes smaller. Researchers will test two new, undisclosed doses below that maintenance level against a placebo.
Not just anyone can join the study. Participants need a body mass index of at least 27, which falls into the overweight or obese range. The study excludes people with type 2 diabetes, along with anyone who’s had major recent weight changes or who already uses other GLP-1 medications like Ozempic or Mounjaro.
So what exactly are researchers measuring? The main goal is weight loss at the 60-week mark. But safety matters too so the team will track side effects and any treatment dropouts through week 67. They’ll also watch secondary factors: waist size, blood pressure, blood sugar levels, and cholesterol numbers.
This isn’t a short project. Novo Nordisk expects the trial to run until 2028, giving the company ample time to gather solid data before making any decisions.
It helps to look at what earlier trials showed. In a previous study, people who stayed on the standard 25 milligram dose lost an average of 16.6% of their body weight after 64 weeks. Those on a placebo lost just 2.7%. That’s a big gap, and it explains why the higher dose became the go-to option. Still, if a lower dose can get patients close to those results, doctors could gain more flexibility when prescribing, especially for people who struggle with side effects at higher strengths.
Cost is clearly part of the equation here, too. Self-paying patients already tend to gravitate toward the lower-dose pills, mainly because they cost about half as much as the higher-strength versions. In fact, more than two-thirds of people currently taking oral Wegovy already use one of the two lowest available doses. That’s a telling number, suggesting patients are already voting with their wallets.
Since launching in the U.S. back in January, the Wegovy pill has racked up more than five million prescriptions. That’s rapid growth by any standard, and it puts Novo Nordisk in a strong position, at least for now.
But competition is heating up. Eli Lilly has been chipping away at Novo Nordisk’s market share, and analysts expect the broader obesity drug market to top $100 billion a year by 2030. That’s a massive prize, and neither company wants to fall behind. Novo Nordisk’s Wegovy pill alone brought in about $499.80 million in the second quarter of this year.
Finding a lower, well-tolerated dose could give the company a real edge. It wouldn’t require developing a brand-new drug, since the FDA has already approved Wegovy. Instead, it’s about fine-tuning what’s already on the market, which tends to move faster and cost less than starting from scratch.
There’s also a public health angle worth mentioning. Some patients already lower their own doses without medical guidance, often to save money or avoid side effects. Regulators don’t recommend that kind of self-adjustment, mainly because it happens without proper oversight. If this trial produces clear, evidence-based results, doctors could finally offer patients a lower-dose option that regulators have actually tested and approved, rather than something patients figure out through trial and error at home.
